Annual CFI
-$39.26 M
-$130.73 M-142.92%
31 December 2023
Summary:
Protagonist Therapeutics annual cash flow from investing activities is currently -$39.26 million, with the most recent change of -$130.73 million (-142.92%) on 31 December 2023. During the last 3 years, it has fallen by -$23.40 million (-147.53%). PTGX annual CFI is now -142.92% below its all-time high of $91.47 million, reached on 31 December 2022.PTGX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$208.71 M
-$120.59 M-136.85%
30 September 2024
Summary:
Protagonist Therapeutics quarterly cash flow from investing activities is currently -$208.71 million, with the most recent change of -$120.59 million (-136.85%) on 30 September 2024. Over the past year, it has dropped by -$147.42 million (-240.55%). PTGX quarterly CFI is now -464.40% below its all-time high of $57.27 million, reached on 30 September 2022.PTGX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$352.05 M
-$195.15 M-124.38%
30 September 2024
Summary:
Protagonist Therapeutics TTM cash flow from investing activities is currently -$352.05 million, with the most recent change of -$195.15 million (-124.38%) on 30 September 2024. Over the past year, it has dropped by -$312.79 million (-796.75%). PTGX TTM CFI is now -405.06% below its all-time high of $115.40 million, reached on 30 September 2022.PTGX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PTGX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -240.6% | -796.8% |
| 3 y3 years | -147.5% | -849.0% | -2119.7% |
| 5 y5 years | +26.9% | -1562.5% | -555.5% |
PTGX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -142.9% | at low | -464.4% | at low | -405.1% | at low |
| 5 y | 5 years | -142.9% | +56.8% | -464.4% | at low | -405.1% | at low |
| alltime | all time | -142.9% | +56.8% | -464.4% | at low | -405.1% | at low |
Protagonist Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$208.71 M(+136.9%) | -$352.05 M(+124.4%) |
| June 2024 | - | -$88.12 M(-1551.5%) | -$156.89 M(+264.8%) |
| Mar 2024 | - | $6.07 M(-109.9%) | -$43.01 M(+9.6%) |
| Dec 2023 | -$39.26 M(-142.9%) | -$61.29 M(+352.0%) | -$39.26 M(-251.2%) |
| Sept 2023 | - | -$13.56 M(-152.6%) | $25.96 M(-73.2%) |
| June 2023 | - | $25.76 M(+162.2%) | $96.80 M(-8.5%) |
| Mar 2023 | - | $9.83 M(+149.7%) | $105.77 M(+15.6%) |
| Dec 2022 | $91.47 M(-676.7%) | $3.94 M(-93.1%) | $91.47 M(-20.7%) |
| Sept 2022 | - | $57.27 M(+64.9%) | $115.40 M(+760.0%) |
| June 2022 | - | $34.73 M(-876.0%) | $13.42 M(-199.1%) |
| Mar 2022 | - | -$4.48 M(-116.1%) | -$13.54 M(-14.6%) |
| Dec 2021 | -$15.86 M(-82.6%) | $27.87 M(-162.3%) | -$15.86 M(-86.6%) |
| Sept 2021 | - | -$44.71 M(-675.2%) | -$118.13 M(-7.4%) |
| June 2021 | - | $7.77 M(-214.4%) | -$127.54 M(-9.2%) |
| Mar 2021 | - | -$6.79 M(-90.9%) | -$140.49 M(+54.4%) |
| Dec 2020 | -$90.97 M(+69.4%) | -$74.40 M(+37.5%) | -$90.97 M(+212.4%) |
| Sept 2020 | - | -$54.12 M(+946.6%) | -$29.12 M(+313.9%) |
| June 2020 | - | -$5.17 M(-112.1%) | -$7.03 M(-53.4%) |
| Mar 2020 | - | $42.73 M(-440.4%) | -$15.09 M(-71.9%) |
| Dec 2019 | -$53.71 M | -$12.55 M(-60.8%) | -$53.71 M(+46.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | -$32.04 M(+142.3%) | -$36.61 M(-784.4%) |
| June 2019 | - | -$13.22 M(-421.9%) | $5.35 M(-81.0%) |
| Mar 2019 | - | $4.11 M(-9.7%) | $28.16 M(+1172.7%) |
| Dec 2018 | $2.21 M(-86.0%) | $4.55 M(-54.1%) | $2.21 M(-8.4%) |
| Sept 2018 | - | $9.92 M(+3.4%) | $2.42 M(-129.2%) |
| June 2018 | - | $9.59 M(-143.9%) | -$8.27 M(+73.4%) |
| Mar 2018 | - | -$21.84 M(-559.7%) | -$4.77 M(-130.2%) |
| Dec 2017 | $15.82 M(-126.7%) | $4.75 M(-715.5%) | $15.82 M(-129.7%) |
| Sept 2017 | - | -$772.00 K(-105.9%) | -$53.25 M(+9.6%) |
| June 2017 | - | $13.09 M(-1147.4%) | -$48.60 M(-28.2%) |
| Mar 2017 | - | -$1.25 M(-98.1%) | -$67.72 M(+14.2%) |
| Dec 2016 | -$59.33 M(+617.9%) | -$64.33 M(-1756.2%) | -$59.33 M(+1821.2%) |
| Sept 2016 | - | $3.88 M(-164.4%) | -$3.09 M(-56.4%) |
| June 2016 | - | -$6.03 M(-184.4%) | -$7.08 M(+537.1%) |
| Mar 2016 | - | $7.15 M(-188.4%) | -$1.11 M(-86.5%) |
| Dec 2015 | -$8.26 M(+2663.9%) | -$8.09 M(+7054.9%) | -$8.26 M(+4516.8%) |
| Sept 2015 | - | -$113.00 K(+85.2%) | -$179.00 K(+171.2%) |
| June 2015 | - | -$61.00 K(+1120.0%) | -$66.00 K(+1220.0%) |
| Mar 2015 | - | -$5000.00 | -$5000.00 |
| Dec 2014 | -$299.00 K | - | - |
FAQ
- What is Protagonist Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly CFI year-on-year change?
- What is Protagonist Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Protagonist Therapeutics?
- What is Protagonist Therapeutics TTM CFI year-on-year change?
What is Protagonist Therapeutics annual cash flow from investing activities?
The current annual CFI of PTGX is -$39.26 M
What is the all time high annual CFI for Protagonist Therapeutics?
Protagonist Therapeutics all-time high annual cash flow from investing activities is $91.47 M
What is Protagonist Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of PTGX is -$208.71 M
What is the all time high quarterly CFI for Protagonist Therapeutics?
Protagonist Therapeutics all-time high quarterly cash flow from investing activities is $57.27 M
What is Protagonist Therapeutics quarterly CFI year-on-year change?
Over the past year, PTGX quarterly cash flow from investing activities has changed by -$147.42 M (-240.55%)
What is Protagonist Therapeutics TTM cash flow from investing activities?
The current TTM CFI of PTGX is -$352.05 M
What is the all time high TTM CFI for Protagonist Therapeutics?
Protagonist Therapeutics all-time high TTM cash flow from investing activities is $115.40 M
What is Protagonist Therapeutics TTM CFI year-on-year change?
Over the past year, PTGX TTM cash flow from investing activities has changed by -$312.79 M (-796.75%)